Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Thursday. The firm set a “sell” rating on the stock. Separately, Mizuho reissued a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Thursday, March 30th. […]

Related Keywords

,Bailard Inc ,Morgan Stanley ,News Ratings For Corvus Pharmaceuticals Daily ,Acadian Asset Management ,Institutional Investors Weigh In On Corvus Pharmaceuticals ,Corvus Pharmaceuticals ,Corvus Pharmaceuticals Stock Performance ,Corvus Pharmaceuticals Inc ,Get Rating ,Street Corp ,Asset Management ,Two Sigma Investments ,Sigma Investments ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Initiated Coverage ,Stocknews Com ,